Research: Investigate FDA/FTC Warning Letters for Functional Beverages

FDA and FTC Enforcement in Functional Beverages

The rapid growth of the functional beverage market—spanning nootropics, prebiotic sodas, and adaptogens—has drawn heightened scrutiny from United States regulatory agencies. To protect consumers from unsubstantiated health claims, undisclosed drug ingredients, and misleading advertising, both the fda (Food and Drug Administration) and the ftc (Federal Trade Commission) actively monitor the market and issue Warning Letters to non-compliant companies. These letters serve as a primary enforcement mechanism to correct violations related to ingredient safety and illegal disease claims.

Regulatory Jurisdiction

The regulatory landscape for functional beverages is jointly overseen by multiple federal agencies, requiring brands to carefully navigate functional-beverage-regulations:

• The fda: Regulates the vast majority of non-alcoholic beverages (any drink containing less than 0.5% ABV, as alcohol above this threshold is regulated by the ttb) [11]. The FDA oversees ingredient safety (such as Generally Recognized as Safe, or GRAS, classifications), product labeling, and manufacturing standards [11].
• The ftc: Exercises oversight over advertising and marketing claims. The FTC ensures that any claims made about a product’s efficacy are truthful, not misleading, and backed by “competent and reliable scientific evidence” [6].

Because functional beverages are often positioned as adult-soft-drinks with added wellness benefits, they blur the lines between conventional foods and dietary supplements. While conventional foods are heavily restricted to claims based on nutritive value, dietary supplements can make claims about non-nutritive effects [13, 14]. However, beverages packaged and sold as conventional foods cannot rely on the dietary supplement pathway without strict formatting changes, exposing many brands to compliance risks [11].

The Core Conflict: structure-function-vs-drug-claims

A primary trigger for FDA warning letters is the violation of the boundary between permissible structure/function claims and illegal drug claims.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), companies may make statements describing how a nutrient or dietary ingredient affects the normal structure or function of the human body (e.g., “calcium builds strong bones” or “supports a calm mood”) [11, 13, 15]. However, they are strictly prohibited from making “disease claims”—statements implying that a product can diagnose, cure, mitigate, treat, or prevent a specific disease [12, 13].

• Permissible Claims: “Mild memory loss associated with aging,” “maintains bowel regularity,” or “helps you unwind” [12, 13].
• Impermissible Drug Claims: “Treats anxiety,” “reduces symptoms of depression,” “cures Alzheimer’s disease,” or “prevents cancer” [10, 11, 12].

Even implied disease claims—such as naming a product with a recognizable portion of a disease name or using words like “cure” or “treat” in the brand name—can trigger regulatory action [12].

Common Triggers for Warning Letters

1. Unsubstantiated Health and Disease Claims

Both the fda and ftc aggressively target companies making baseless health claims. The agencies have sent joint warning letters to companies (such as Gold Crown Natural Products, TEK Naturals, and Pure Nootropics) for falsely claiming their supplements and functional products could treat Alzheimer’s, Parkinson’s, heart disease, or cancer [10]. Specific cited claims included phrases like “helps prevent cancer,” “slows the buildup of plaque deposits,” and “great for brain injury recovery” [10].

The ftc has also taken legal action against marketers using fake endorsements or fraudulent clinical studies. In the case of memory-boosting supplement CogniPrin, the FTC and the Maine Attorney General penalized marketers for falsely claiming their product could “roll back mental decline by as much as 12 years” and “improve memory by 44 percent,” utilizing a fake “brain scientist” to lend false authority [9]. Similarly, companies attempting to capitalize on health crises by claiming their products treat or prevent COVID-19 have faced immediate FTC consent orders and FDA warning letters [6, 8].

2. Unapproved and Non-GRAS Ingredients

Warning letters are frequently issued when companies use ingredients in conventional foods and beverages that are not prior-sanctioned or classified as GRAS. For example, the FDA sent warning letters to functional food makers (such as U.S. Mills and Fresh Samantha) for utilizing Ginkgo biloba, echinacea, and Siberian ginseng (eleuthero) in juices and cereals, noting that the agency was uncertain of any basis for concluding these botanicals were GRAS for conventional food use [1].

3. Illegally Marketed cannabis-beverages and CBD

The FDA has maintained a strict stance against the introduction of CBD into the conventional food and beverage supply. The agency routinely issues warning letters to companies illegally selling foods and beverages containing CBD [4]. The FDA has expressed particular concern over CBD products packaged in ways that mimic traditional foods (like gummies, sodas, and candies), which increases the risk of unintentional overconsumption, especially by children [4]. Between 2015 and 2022, dozens of companies in the CBD space received warning letters for illegally marketing unapproved CBD products, often compounded by claims that the CBD mitigated or treated diseases [2, 4].

Impact on adaptogens and Nootropics

The modern boom in functional beverages—including those produced by brands like curious-elixirs—relies heavily on botanical ingredients like Ashwagandha, Cordyceps, and Rhodiola rosea [6]. These beverages are often marketed as alternatives to alcohol that promise stress relief and mood enhancement [6].

However, medical professionals and psychiatrists note a significant “discovery gap” regarding efficacy: because these drinks are usually categorized as dietary supplements, they are not systematically reviewed by the FDA prior to hitting shelves [3]. Furthermore, there is often insufficient clinical research to prove that the beverage-sized doses of adaptogens and nootropics actually provide the measurable, physiological benefits claimed on the packaging [3]. To survive regulatory scrutiny, companies must utilize careful “mood-boosting” or “mind-calming” structure/function phrasing while completely avoiding any terminology linked to clinical anxiety, depression, or disease mitigation [6].

Enforcement Mechanisms and Penalties

When the FDA issues a Warning Letter, the offending company typically has 15 working days to respond [1, 4]. The response must outline specific steps taken to correct the violations, such as submitting revised product labels or removing disease claims from websites and social media channels [1, 4].

If a company fails to comply, they face severe legal actions, including:

• Product Seizure and Injunctions: The FDA can physically seize non-compliant products and halt manufacturing [4].
• Civil Penalties: The ftc can issue binding consent orders with the force of law. Violating an FTC order can result in massive civil penalties (up to $46,517 per violation) and lifetime bans from the supplement or functional beverage industry [7].

Gaps and Contradictions in the Regulatory Framework

• Pre-Market Approval vs. Post-Market Enforcement: A significant contradiction in the functional beverage market is the lack of pre-market FDA approval for dietary supplements, contrasting sharply with aggressive post-market enforcement. Brands can launch products with untested adaptogenic claims rapidly, but risk severe retroactive penalties once the FDA or FTC conducts an audit [3, 13].
• Beverage vs. Supplement Ambiguity: There remains ongoing industry confusion regarding when a liquid is a conventional beverage (requiring GRAS ingredients and purely nutritive structure/function claims) versus a liquid dietary supplement (which allows for non-nutritive botanical claims). The FDA looks heavily at packaging, product name, and volume to determine the classification, often catching brands off-guard [11, 14].

Additional Sources Worth Finding

To expand upon this topic, future research should seek out:

• Specific FTC substantiation guidelines for cognitive and mood-enhancing claims in liquid formats.
• Case studies of functional beverage companies that successfully petitioned the FDA for GRAS status for novel nootropic ingredients.
• Data on consumer perception of structure-function-vs-drug-claims and whether buyers understand the regulatory difference between “supports focus” and “cures ADHD.”

References

1. FDA Sends Warning Letters to Functional Food Makers — supplysidesj.com
2. Warning Letters for Cannabis-Derived Products | FDA — fda.gov
3. What Functional Beverages Can—and Can’t—Do for Overall Wellness — eatingwell.com
4. FDA Warns Companies for Illegally Selling Food and Beverage Products that Contain CBD | FDA — fda.gov
5. Warning Letters Related to Food, Beverages, and Dietary … - FDA — fda.gov
6. Adaptogens & FDA/FTC Compliance: What You Need to Know — cohenhealthcarelaw.com
7. FTC Proposed Order Stops Marketers from Continuing to Promote Supplements Using Baseless Health Claims | Federal Trade Commission — ftc.gov
8. FTC Approves Final Administrative Consent Order with Marketer of Product Falsely Claiming to Prevent or Treat COVID-19 | Federal Trade Commission — ftc.gov
9. Trial and error | Federal Trade Commission — ftc.gov
10. FTC and FDA Sent Warning Letters to Companies Advertising Products that Claim Treatment of Disease - Davis+Gilbert LLP — dglaw.com
11. Frequently Asked Questions About Non-Alcoholic Beverage … — vicentellp.com
12. Small Entity Compliance Guide on Structure/Function Claims - FDA — fda.gov
13. Structure/Function Claims - FDA — fda.gov
14. [PDF] Guidance-for-Industry—Distinguishing-Liquid-Dietary-Supplements … — fda.gov
15. [PDF] The FDA’s Treatment of Structure/Function Claims under the Dietary … — dash.harvard.edu